89zr-dfo-mstp2109a - a radioimmunoconjugate composed of the radioisotope zirconium zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (steap1) that can potentially be used as a prostate cancer tracer during positron emission tomography (pet). Upon administration of zirconium zr 89 dfo-mstp2109a, the antibody moiety dfo-mstp2109a binds to steap1 on prostate cancer cells. In turn, zr 89 allows for the visualization of those cells using pet. Steap1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells. Also see zirconium zr 89 dfo-mstp2109a
Up to date info
Latest research - 89zr-dfo-mstp2109a
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr-dfo-mstp2109a for any updates.